Why the Challenger Ltd share price could hit new highs in 2017

The Challenger Ltd (ASX:CGF) share price has posted a strong 12 months.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shareholders of annuities provider Challenger Ltd (ASX: CGF) have experienced impressive returns over the past 12 months, with its market price rallying by more than 70%. I must admit it has been rewarding, as a shareholder myself, watching the convergence of price and value over such a short period.

Australia has an aging population which we all know is entering retirement. Consequently, there will be greater demand for certain services that cater towards the needs of retirees.

The number of Australians over the age of 65 is projected to double within the next two decades. Because of this demographic trend it is expected that the superannuation industry will quintuple over the next two decades from around $2 trillion to $10 trillion.

Obviously, demand for life-time annuities will also increase with the majority of annuity sales made to consumers who have just entered retirement. In Australia, the number of retirees with fixed income is only 9 percent, however, in other developed nations the average is approximately 52 percent. If Australia were to reach parity with other developed nations, this too would benefit Challenger.

To put this into perspective, if the number of Australian retirees with fixed income were closer to 50%, Challenger's earnings would increase by at least five-fold.

Challenger currently holds circa 70% market share in lifetime annuities and assets under management amount to more than $60 billion.

It's evident Challenger is a business with bright prospects. Its dominant position in the market would make it difficult for Challenger not to do well over the next two decades.

However, if the conventional view is such, wouldn't its potential be baked into its price already? In other words, isn't it likely that you're already paying for the potential growth Challenger is likely to experience?

Well, not quite. I still believe if you were to purchase shares in Challenger today you could still expect modest returns over the longer term. I still believe there is a discrepancy between Challenger's intrinsic value and its market price.

If the superannuation industry does indeed achieve a compounded annual growth rate (CAGR) of approximately 8% over the next two decades, then it would be reasonable to suggest that Challenger can grow its earnings at an equivalent rate.

Assuming Challenger can grow its earnings at an average CAGR of between 6-8% per annum over the next decade, and then grow its earnings perpetually at 3% per annum over its life time, I estimate Challenger's intrinsic value lies somewhere between $11.69 and $13.56 per share.

At today's price of $11.64, Challenger shares are currently trading at a discount to its intrinsic value of between 0.4 percent and 14 percent.

Whilst you could argue Challenger shares are still good value for money, since they can be purchased just below intrinsic value, I would argue that the margin of safety (discrepancy between price and value) is insufficient.

I emphasise the importance of purchasing a security only once it can be purchased at a significant discount to its intrinsic value. This is because evaluating a business's future requires making predictions and the tricky job of the analyst is in predicting. As Yogi Berra once pointed out, "It's tough to make predictions, especially about the future".

While I always take a conservative approach to forecasting, inevitable, unforeseen circumstances do arise from time-to-time. The larger the margin of safety, the greater buffer available to fall back on if my analysis is wrong.

Foolish takeaway

Whilst Challenger is certainly no bargain at its current price, a drop in share price below $10 could present an excellent buying opportunity for investors.

Motley Fool contributor Trent Daly owns shares of Challenger Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »